Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 9/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PFKFB4 | Q16877 | 5/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PRF1 | P14222 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6717937 | 0.91 | MEN1 (0.49) | PFKFB3MAPTMEN1KMT2AF10 | |
| SCHEMBL7067510 | 0.90 | PFKFB3 (0.52) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL6718575 | 0.89 | PFKFB3 (0.52) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL6780301 | 0.88 | PFKFB3 (0.55) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL6714757 | 0.84 | PFKFB3 (0.52) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL7065243 | 0.79 | LMNA (0.39) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL6714983 | 0.79 | CDK1 (0.50) | PFKFB3MEN1KMT2APFKFB4TP53 | |
| SCHEMBL6720500 | 0.79 | TSHR (0.50) | PFKFB3MAPTMEN1KMT2APRF1 | |
| SCHEMBL6724818 | 0.79 | KMT2A (0.52) | PFKFB3MAPTMEN1KMT2APFKFB4 | |
| SCHEMBL6716663 | 0.77 | ERAP1 (0.48) | MAPTMEN1KMT2ATP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6818651-B2 | ANTIINFLAMMATORY, ANTIASTHMATIC, SKIN, AND AUTOIMMUNE DISORDERS; CROHN*S DISEASE, ULCERATIVE COLITIS, CONJUCTIVITIS, MULTIPLE SCLEROSIS, AND RHEUMATOID ARTHRITIS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE | ALTANA PHARMA AG (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | ALTANA PHARMA AG (DE) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044212-A1 | (Dihydro) Isoquinoline derivatives as phosphodiesterase inhibitors | PDE7B, PDE3B, PDE3A | PFKFB3 2298/4885MAPT 4033/4885MEN1 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.